We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

James Crawford - Director and Senior Principal Scientist (Chemistry), Discovery Chemistry

James Crawford

Director and Senior Principal Scientist (Chemistry), Discovery Chemistry

"The opportunity to do innovative research to discover transformational therapies with talented, passionate scientists makes Genentech a special place."
Years at Genentech
Publications at Genentech
Awards & Honors

I am a Director and Project Team Leader in our small molecule drug discovery group. I was born and raised in Glasgow, Scotland, and obtained my MSci and Ph.D. degrees in chemistry from the University of Strathclyde. In 2005, I joined Professor K.C. Nicolaou’s laboratory at The Scripps Research Institute as a Fulbright scholar, before starting my industrial career in 2006 with AstraZeneca in their Respiratory and Inflammation group. At Genentech I'm excited by the opportunity to do leading-edge research with world class biologists and drug hunters every day.

Featured Publication

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton0s Tyrosine Kinase Inhibitor in Early Clinical Development.

J Med Chem. 2018 Mar 22;61(6):2227-2245.

Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.